Visual performance and quality of vision with a toric extended-range-of-vision intraocular lens
Session Details
Session Title: Moderated Poster Session: The New Enlarged Depth-of-Focus Technology
Venue: Poster Village: Pod 1
First Author: : K.Gundersen NORWAY
Co Author(s): :
Abstract Details
Purpose:
To evaluate visual and refractive outcome as well as patient satisfaction of patients with bilateral implantation of the TECNIS Symfony toric intraocular lens (IOL).
Setting:
Ifocus eye clinic, Haugesund, Norway, single site, single surgeon
Methods:
Thirty patients (60 eyes) with bilateral regular corneal astigmatism of 0.75 to 2.60 D were enrolled in this mono-centered prospective study. Emmetropia was targeted in all patients. Follow-up visits were scheduled 1 day, 1 week and 3 months after bilateral implantation of the TECNIS Symfony toric IOL.
Main outcome parameters were Uncorrected (UDVA), best-corrected (CDVA) distance visual acuity as well as uncorrected intermediate (UIVA) and near (UNVA). Other study parameters included subjective refraction, decentration/tilt, photic phenomena, spectacle use, patient (VFQ-25) and surgeon satisfaction. Visual acuity values are presented in decimal notation.
Results:
Mean age was 58.9±7.94 years, mean preoperative cylinder -1.86±1.0 D. Mean 3-month binocular UDVA and CDVA were 1.07 and 1.16, respectively. Binocular UIVA and UNVA were 1.07 and 0.99, respectively. IOL rotation was 3.0° (median) between month 3 and surgery. No decentrations or tilt occurred.
One patient reported slight problems during night driving, one patient mild halos and glare and one patient slightly reduced visual acuity. More than 92% of the patiens reported no or only occasionally use of spectacles for distance and more than 96% for intermediate or near vision tasks.
Conclusions:
The TECNIS Symfony toric extended range of vision IOL provided excellent uncorrected visual acuity across distances. Positional stability of the IOL was very high. Visual symptoms occurred rarely and were mild. Patients were very satisfied with the procedure and outcome.
Financial Disclosure:
-
